Enabling Technologies Consortium
Enabling Technologies Consortium is a member-governed, pre-competitive collaboration forum of 16 major pharmaceutical and biotechnology companies that jointly identify, fund, and develop scientific tools and techniques for pharmaceutical CMC and drug product development.
- Company typePrivate
- Founded2015
- HeadquartersWashington, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Enabling Technologies Consortium does
The Enabling Technologies Consortium (ETC), founded in 2015 (also cited as 2016) and headquartered in Washington, United States, is a pre-competitive collaboration forum comprising 16 major pharmaceutical and biotechnology companies—including AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Genentech/Roche, GSK, Gilead, Johnson & Johnson, Merck, Novartis, Pfizer, Takeda, and Zoetis. It is not a product company; it operates as a member-governed consortium that identifies, evaluates, develops, and improves scientific tools and techniques supporting pharmaceutical chemistry, manufacturing, and control (CMC) and drug product development. ETC evolved from the ETC Working Group formed within the API Leadership group of the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ Consortium).
ETC's operating model centers on eight discipline-specific Working Groups (Analytical & Purification, Crystallization, Computational and Data Sciences, Novel Chemistry Reaction Environment, High Throughput Experimentation, Drying, Solubility, and Drug Product) that identify technology gaps and propose collaborative projects. Projects are executed through a structured Request for Information/Request for Proposals (RFI/RFP) process governed by Board-approved charters and standardized Development Agreements, with cross-pharma subject matter experts assembled into Project Teams to vet solutions. External collaborators (vendors, academics, government labs) partner on development; ETC does not retain IP from these collaborations, and results are disseminated broadly through publications and partner commercialization.
The business model is community-led and membership-based. Revenue derives from annual membership fees ($25,000 per company for 2023, open to any company with an active NDA) and project cost-sharing among participating members, with ETC providing seed funding of historically $0–$400,000 per project spread over 1–3 years. Its core value proposition is eliminating the need for parallel bilateral agreements between each pharma company and external parties, providing a governance framework, and enabling equitable, pooled investment in enabling-technology development across the industry.
Enabling Technologies Consortium firmographics
Firmographics- Name
- Enabling Technologies Consortium
- Legal name
- Enabling Technologies Consortium
- Website
- https://etconsortium.org
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Enabling Technologies Consortium is a member-governed, pre-competitive collaboration forum of 16 major pharmaceutical and biotechnology companies that jointly identify, fund, and develop scientific tools and techniques for pharmaceutical CMC and drug product development.
- Ownership category
- akta.pro rank
Enabling Technologies Consortium industry classification
Industry- Product category
- Pharmaceutical R&D Consortium Services
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
- akta.pro secondary industry
- CMC Regulatory Affairs (Modules 2/3, Variations, Post-Approval CMC) (HLAGAKAB)
Keywords
Where Enabling Technologies Consortium is headquartered
LocationHeadquarters
- HQ city
- Washington
- HQ country
- United States
- HQ region
- North America
Markets served
Enabling Technologies Consortium business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Operations, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- Membership Fees: Annual membership fees charged to pharmaceutical and biotechnology companies. For 2023, the membership fee is $25,000 per year. Any company with an active new drug application (NDA) can become a member.
- Project Cost Sharing: Project costs are shared among participating member companies, leading to significant cost savings. External collaborators may receive seed funding from ETC, though the collaborator also invests in the project. ETC does not retain IP from collaborations.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Annual Membership Fee |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Enabling Technologies Consortium product offering
Product offeringCore offering
ETC is a pre-competitive collaboration consortium for pharmaceutical and biotechnology companies that facilitates the identification, evaluation, development, and improvement of scientific tools and techniques supporting pharmaceutical chemistry, manufacturing, and control (CMC). It operates through eight discipline-specific Working Groups and uses a structured RFI/RFP process to engage external collaborators (vendors, academics, government labs) in joint technology development projects, with costs shared among member companies.
Product overview
The Enabling Technologies Consortium (ETC) is a pre-competitive collaboration consortium—not a product company. It functions as a forum for pharmaceutical and biotechnology companies to identify, evaluate, develop, and improve scientific tools and techniques that support efficient pharmaceutical development and manufacturing. ETC's core offerings include eight discipline-specific Working Groups (Analytical and Purification, Crystallization, Computational and Data Sciences, Novel Chemistry Reaction Environment, High Throughput Experimentation, Drying, Solubility, and Drug Product), a structured RFI/RFP collaboration process for soliciting project proposals, and Project Teams that execute collaborative technology development initiatives. The consortium also provides knowledge resources through publications, presentations, and annual recognition awards. ETC streamlines partnerships by eliminating the need for parallel agreements between member companies and external parties, providing governance frameworks for collaborative projects.
Differentiator
Problem solved
Functional benefit
Products and services
- Annual Consortium Membership
- Project Team Collaborations
- RFI/RFP Collaboration Solicitation
- Collaboration Opportunities Portal
Companies that use Enabling Technologies Consortium
Customer profileNamed customers16 records
Segments1 record
Ideal customer profiles2 records
Enabling Technologies Consortium technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Enabling Technologies Consortium partnerships and signals
Strategic signalPartnerships
18 partnerships are on record, tiered foundational and core.
- International Consortium for Innovation and Quality in Pharmaceutical Development (IQ Consortium)foundationalThe ETC was founded in 2015 as an evolution of the ETC Working Group formed within the Active Pharmaceutical Ingredient (API) Leadership group of the IQ Consortium. The IQ Consortium brought together scientists from various pharmaceutical companies for pre-competitive discussion.
- AbbViecoreOne of 16 member companies of the Enabling Technologies Consortium. AbbVie participates in Working Groups (e.g., Analytical & Purification, Crystallization, Drug Product, High Throughput Experimentation) and provides subject matter experts for project teams.
- AmgencoreOne of 16 member companies of the Enabling Technologies Consortium.
- AstraZenecacoreOne of 16 member companies of the Enabling Technologies Consortium.
- BiogencoreOne of 16 member companies of the Enabling Technologies Consortium.
- Boehringer IngelheimcoreOne of 16 member companies of the Enabling Technologies Consortium. Boehringer Ingelheim participates in the Novel Chemistry Reactor Environment Working Group.
- Bristol Myers SquibbcoreOne of 16 member companies of the Enabling Technologies Consortium. Bristol Myers Squibb participates in multiple Working Groups including Crystallization and provides Board representation.
- Eli Lilly & Co.coreOne of 16 member companies of the Enabling Technologies Consortium. Eli Lilly participates in Analytical & Purification, Data Curation Workbench, and other Working Groups.
- Genentech/RochecoreOne of 16 member companies of the Enabling Technologies Consortium. Genentech participates in Crystallization, Drug Product, and other Working Groups, and provides Board representation.
- GSKcoreOne of 16 member companies of the Enabling Technologies Consortium. GSK participates in multiple Working Groups including Analytical & Purification, Crystallization, Drug Product, High Throughput Experimentation, and Solubility.
- GileadcoreOne of 16 member companies of the Enabling Technologies Consortium.
- Johnson & JohnsoncoreOne of 16 member companies of the Enabling Technologies Consortium.
- MerckcoreOne of 16 member companies of the Enabling Technologies Consortium. Merck participates in Solubility Working Group and provides expertise for projects including Portable Low Field NMR.
- NovartiscoreOne of 16 member companies of the Enabling Technologies Consortium.
- Pfizer, Inc.coreOne of 16 member companies of the Enabling Technologies Consortium. Pfizer participates in Crystallization Working Group.
- TakedacoreOne of 16 member companies of the Enabling Technologies Consortium. Takeda participates in Novel Chemistry Reactor Environment Working Group.
- ZoetiscoreOne of 16 member companies of the Enabling Technologies Consortium. Zoetis participates in Visibility Committee and provides Board representation.
- External Vendors and Academic InstitutionscoreExternal collaborators including vendors, academics, and government laboratories partner with ETC on specific technology development projects through RFI/RFP process. Collaborations can be zero-cost or involve ETC funding. IP resides with the collaborator; ETC does not retain IP from third-party collaborations.
Scale indicators4 records
Recent moves5 records
Expansion highlights5 records
Enabling Technologies Consortium competitors and assessment
Company assessmentDirect peers
- BioPhorum: Pharma consortium operating across multiple 'Phorums' (e.g., BioPhorum Development Group, Drug Substance) addressing shared CMC, manufacturing, and supply chain challenges. Closely mirrors ETC's pre-competitive collaboration model.
- Critical Path Institute (C-Path): Pre-competitive consortium partnering with pharma, regulators, and academics to accelerate drug development through shared data and methods — directly comparable in convening role and pharma member base.
- TransCelerate BioPharma: Pharma consortium tackling shared clinical development challenges via collaborative solutions — directly comparable as a member-funded pre-competitive forum with overlapping big-pharma membership.
- International Consortium for Innovation and Quality in Pharmaceutical Development (IQ Consortium): The parent organization from which ETC was spun out; a pre-competitive pharma consortium focusing on similar CMC, regulatory, and drug development topics. Direct peer in mission and member overlap, though broader in scope.
- Pistoia Alliance: Pre-competitive life sciences consortium focused on R&D innovation, including data, AI, and lab informatics — directly comparable as a member-funded collaboration forum convening pharma companies around shared technology challenges.
Broad incumbents
- Drug Information Association (DIA): Global life sciences association covering drug development and regulatory topics; broader than ETC but serves overlapping pharma member companies and addresses adjacent CMC, regulatory, and drug development content.
- Pharmaceutical Research and Manufacturers of America (PhRMA): Trade association representing major US pharma companies; broader than ETC but shares a substantial portion of the membership base and influences pre-competitive research policy direction.
- International Society for Pharmaceutical Engineering (ISPE): Large established industry association covering pharmaceutical engineering, manufacturing, and quality. Broader in scope than ETC but addresses overlapping CMC, drug product, and manufacturing technology topics for many of the same member companies.
Emerging players
- National Institute for Pharmaceutical Technology & Education (NIPTE): Academic consortium advancing pharmaceutical manufacturing science and engineering education/research; overlaps with ETC's mission on enabling technologies for pharma development and manufacturing.
- CASSS (California Separation Science Society): Non-profit scientific community focused on separation sciences and pharmaceutical analysis; overlaps with ETC's Analytical & Purification and Solubility working group themes and serves many of the same pharma scientists.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Enabling Technologies Consortium social profiles
Digital presenceEnabling Technologies Consortium financial estimates
Financial estimateRevenue estimate
Valuation estimate
Enabling Technologies Consortium leadership team
Management profileNumber of profiles
Profiles4 records
Enabling Technologies Consortium funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Enabling Technologies Consortium M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Enabling Technologies Consortium
What does Enabling Technologies Consortium do?
ETC is a pre-competitive collaboration consortium for pharmaceutical and biotechnology companies that facilitates the identification, evaluation, development, and improvement of scientific tools and techniques supporting pharmaceutical chemistry, manufacturing, and control (CMC). It operates through eight discipline-specific Working Groups and uses a structured RFI/RFP process to engage external collaborators (vendors, academics, government labs) in joint technology development projects, with costs shared among member companies.
Is Enabling Technologies Consortium a public or private company?
Enabling Technologies Consortium is a private company. It is classified as corporate owned and is currently operating.
When was Enabling Technologies Consortium founded?
Enabling Technologies Consortium was founded in 2015. It employs 51 to 100 people.
Where is Enabling Technologies Consortium based?
Enabling Technologies Consortium is headquartered in Washington, United States, in the North America region.
How does Enabling Technologies Consortium make money?
Two revenue lines are on record. Membership Fees are the primary driver. The others are project Cost Sharing.
Who are Enabling Technologies Consortium's main competitors?
Direct peers on record are BioPhorum, Critical Path Institute (C-Path), TransCelerate BioPharma, International Consortium for Innovation and Quality in Pharmaceutical Development (IQ Consortium) and Pistoia Alliance. Broad incumbents are Drug Information Association (DIA), Pharmaceutical Research and Manufacturers of America (PhRMA) and International Society for Pharmaceutical Engineering (ISPE). Emerging players are National Institute for Pharmaceutical Technology & Education (NIPTE) and CASSS (California Separation Science Society).
Does Enabling Technologies Consortium have an API?
No public API is recorded for Enabling Technologies Consortium.
What industry is Enabling Technologies Consortium in?
Enabling Technologies Consortium's product category is Pharmaceutical R&D Consortium Services. Its primary akta.pro industry code is HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC), with a secondary code of HLAGAKAB, CMC Regulatory Affairs (Modules 2/3, Variations, Post-Approval CMC). Its NAICS code is 54171 and its SIC code is 8731.